StockNews.AI
SIGA
StockNews.AI
110 days

SIGA to Host Business Update Call on May 8, 2025 Following Release of First-Quarter 2025 Results

1. SIGA hosts a business update conference call on May 8, 2025. 2. CEO Diem Nguyen and CFO Daniel Luckshire will lead the call. 3. TPOXX® approved for smallpox and monkeypox treatment. 4. SIGA focuses on infectious diseases among global health threats. 5. Webcast available on SIGA's website; replay offered for two weeks.

Earnings
+1.63%Current Return
VS
+2.37%S&P 500
$5.5205/01 07:49 AM EDTEvent Start
$5.6105/02 02:22 PM EDTLatest Updated
4m saved
Insight
Article

FAQ

Why Bullish?

The upcoming business update suggests potential positive developments or strategic news that could boost confidence among investors, reminiscent of previous calls that resulted in stock price increases aligning with key announcements.

How important is it?

The business update could directly influence investor perception and stock performance, driving significant short-term interest. Information disclosed could affect market sentiment and trading volume depending on the magnitude of the announcements.

Why Short Term?

The timing of the conference call is immediate, with potential reactions likely occurring shortly after the event. Historical patterns often show stock price movements following scheduled updates, particularly when expectations are set for new insights or developments.

Related Companies

VRSNAMCR
May 01, 2025 07:30 ET  | Source: SIGA Technologies Inc. NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, May 8, 2025. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer. A live webcast of the call will also be available on the Company's website at http://www.siga.com in the Investor Relations section of the site, or by clicking here. Please log in approximately 5-10 minutes prior to the scheduled start time. Participants may access the call by dialing 1-800-717-1738 for domestic callers or 1-646-307-1865 for international callers. A replay of the call will be available for two weeks by dialing 1-844-512-2921 for domestic callers or 1-412-317-6671 for international callers and using Conference ID: 1160299. The archived webcast will be available in the Investor Relations section of the Company's website. About SIGA SIGA is a commercial-stage pharmaceutical company and leader in global health focused on the development of innovative medicines to treat and prevent infectious diseases. With a primary focus on orthopoxviruses, we are dedicated to protecting humanity against the world’s most severe infectious diseases, including those that occur naturally, accidentally, or intentionally. Through partnerships with governments and public health agencies, we work to build a healthier and safer world by providing essential countermeasures against these global health threats. Our flagship product, TPOXX® (tecovirimat), is an antiviral medicine approved in the U.S. and Canada for the treatment of smallpox and authorized in Europe, the UK, and Japan for the treatment of smallpox, mpox (monkeypox), cowpox, and vaccinia complications. For more information about SIGA, visit www.siga.com. Contacts: Suzanne Harnett sharnett@siga.com    and   InvestorsMediaJennifer Drew-Bear, Edison GroupJdrew-bear@edisongroup.comHolly Stevens, CG Life hstevens@cglife.com

Related News